Godefridus J Peters

To Combine or Not Combine: Drug Interactions and Tools for Their Analysis. Reflections from the EORTC-PAMM Course on Preclinical and Early-phase Clinical Pharmacology

Giulia Mantini, Elisa Giovannetti, Btissame El Hassouni, 2019, AntiCancer Research.

Gemcitabine chemoresistance in pancreatic cancer: Molecular mechanisms and potential solutions

Godefridus J Peters, G. Peters, R. Andersson, 2009, Scandinavian journal of gastroenterology.

Thymidylate synthase inhibitors for non-small cell lung cancer

Elisa Giovannetti, Godefridus J Peters, E. Giovannetti, 2011, Expert opinion on investigational drugs.

The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.

Ursula Creutzig, Gudrun Fleischhack, Godefridus J Peters, 2004, International journal of oncology.

Guidelines for the use and interpretation of assays formonitoring autophagy (3rd edition)

Sangeeta Khare, Xin Qi, Ying Wang, 2016 .

MicroRNA-21 in pancreatic cancer: correlation with clinical outcome and pharmacologic aspects underlying its role in the modulation of gemcitabine activity.

Ugo Boggi, Elisa Giovannetti, Godefridus J Peters, 2010, Cancer research.

In vivo induction of resistance to gemcitabine results in increased expression of ribonucleotide reductase subunit M1 as the major determinant.

Bauke Ylstra, Godefridus J Peters, G. Peters, 2005, Cancer research.

Determinants of resistance to 2',2'-difluorodeoxycytidine (gemcitabine).

Godefridus J Peters, G. Peters, A. Bergman, 2002, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.